New drug cocktail aims to fight Hard-to-Treat cancers
NCT ID NCT07241936
First seen Nov 21, 2025 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This study tests a combination of sirolimus (a targeted therapy) with several antibody-drug conjugates (ADCs) in people with advanced solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the combo can shrink tumors. About 444 participants will be enrolled in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (albumin-bound) combined with antibody-drug conjugates (DP303c, SYS6043, SYS6002, SYS6010)
What this could lead to
If successful, this could point toward a new combination treatment option for advanced solid tumors that are hard to treat.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of patients, so safety and effectiveness are not yet proven. The combination may cause significant side effects or fail to shrink tumors.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.